Meta-analysis indicates infections contributed to 2.3 million cancer cases in 2024 — Evidence Review
Published in The Lancet Oncology
Researched by
— the AI search engine for science
Table of Contents
About one in eight cancer cases worldwide are caused by infections, according to a new study; this finding aligns with previous global estimates, suggesting infection prevention could substantially reduce cancer rates. Most related studies agree with the new results from The Lancet Oncology, though the exact fraction varies over time and by region.
- Earlier research estimated that infections accounted for 15–18% of global cancer cases in previous years, with the burden being especially high in less developed regions and among certain cancer types 1 2 3 4 5.
- The most significant cancer-causing pathogens consistently include Helicobacter pylori, hepatitis B and C viruses, and human papillomavirus, which together account for the majority of infection-related cancers 1 2 3 4 5 11.
- Vaccination and infection control have been repeatedly highlighted in the literature as effective strategies for reducing the incidence of infection-related cancers, and real-world data show vaccines such as the HPV vaccine are highly effective at prevention 6 7 8 10.
Study Overview and Key Findings
Understanding the proportion of cancers caused by infectious agents is crucial for guiding prevention strategies. The 2024 meta-analysis from The Lancet Oncology is particularly timely as it quantifies the current global burden of infection-attributable cancers and highlights pathogens with the highest impact. With ongoing advances in vaccination and infection control, this study provides updated evidence to inform public health policy and resource allocation.
| Property | Value |
|---|---|
| Study Year | 2024 |
| Journal Name | The Lancet Oncology |
| Population | Cancer cases caused by infections |
| Methods | Meta-Analysis |
| Outcome | Impact of cancer-causing pathogens on cancer rates |
| Results | Infections drove about 2.3 million new cancer cases in 2024 |
Literature Review: Related Studies
To situate the new study within the broader scientific context, we searched the Consensus database of over 200 million research papers using the following queries:
- cancer cases infections associations
- vaccines cancer prevention effectiveness
- infectious agents cancer risk factors
Below is a summary of key topics and findings from the related literature:
| Topic | Key Findings |
|---|---|
| What proportion of cancers are attributable to infections globally? | - Estimates from 2002 to 2018 place the infection-attributable cancer burden at 12–18% of cases, with regional variation and a trend toward a modest decline over time 1 2 3 4 5. - Helicobacter pylori, HPV, hepatitis B/C, and EBV are the principal agents 1 2 3 4 5 11. |
| How effective are vaccines and prevention strategies for infection-related cancers? | - HPV vaccination dramatically reduces cervical cancer incidence, especially when administered at younger ages 6 7. - Broader implementation of vaccination and infection control could prevent a substantial portion of cancer cases worldwide 3 7 8 10. |
| Which pathogens are most implicated in cancer and what cancers do they cause? | - Helicobacter pylori (stomach), HBV/HCV (liver), HPV (cervix), and EBV (various lymphomas and nasopharyngeal carcinoma) are the main infectious agents linked to cancer 1 2 3 5 11 12. - Associations with other agents (e.g., HIV, KSHV, parasites) are well-documented 2 5 11. |
| What are the challenges and research gaps in preventing infection-related cancers? | - Disease burden is underestimated due to conservative estimates and unrecognized infectious agents 5. - Long-term effectiveness of vaccines beyond cervical cancer, the role of cofactors, and region-specific risk profiles remain areas needing clarification 7 9 12. |
What proportion of cancers are attributable to infections globally?
The new study’s estimate that about 12% of cancers are infection-related closely matches prior global assessments, though historical estimates have ranged from 12% to nearly 18% depending on study year, methodology, and geographic focus 1 2 3 4 5. Regional variation is pronounced, with higher fractions in lower-income regions, reflecting disparities in infection prevalence and access to preventive measures.
- Multiple global analyses over the past two decades have consistently found that 12–18% of new cancer cases are attributable to infections, with the absolute number of cases rising in tandem with overall cancer incidence 1 2 3 4.
- Helicobacter pylori, HPV, HBV, and HCV are consistently identified as the most significant contributors, collectively responsible for the majority of infection-attributable cancers 1 2 3 4 5.
- The infection-attributable cancer burden is highest in regions such as sub-Saharan Africa and eastern Asia, and lowest in North America, Western Europe, and Oceania 1 3 4.
- The burden has declined slightly as a proportion of total cancers in higher-income countries due to improved infection control and vaccination 1 4.
How effective are vaccines and prevention strategies for infection-related cancers?
The literature shows strong evidence that vaccination programs, especially against HPV and hepatitis viruses, significantly reduce incidence of related cancers. The new study underscores vaccination as a key prevention strategy, in line with real-world effectiveness data 6 7 8 10.
- HPV vaccination is highly effective in preventing cervical cancer, particularly when given before sexual activity begins; vaccine effectiveness diminishes with increasing age at vaccination 6 7.
- Vaccines targeting hepatitis B have reduced liver cancer rates in countries with high vaccine coverage, and similar approaches are under development for other pathogens 8 10.
- Combination strategies including vaccination, screening, and antimicrobial treatment are advocated to maximize reduction in infection-related cancers 3 8 10.
- Long-term effectiveness and implementation challenges remain, particularly for cancers other than the cervix and in resource-limited settings 7 9 10.
Which pathogens are most implicated in cancer and what cancers do they cause?
Research consistently identifies a small set of infectious agents as the predominant causes of infection-associated cancers, with clear evidence for their causal roles in specific malignancies 1 2 3 5 11 12.
- Helicobacter pylori is the leading cause of stomach cancer, especially in East Asia 1 2 3 4 5.
- Human papillomavirus is responsible for nearly all cervical cancer cases and a substantial proportion of other anogenital and oropharyngeal cancers 1 2 3 5 6 7 11.
- Hepatitis B and C viruses are the primary infectious drivers of liver cancer and are also implicated in some lymphomas 1 2 3 5 11.
- Epstein-Barr virus is associated with several lymphomas, nasopharyngeal carcinoma, and a subset of gastric cancers 11 12.
- Other pathogens, such as schistosomes and liver flukes, account for smaller but regionally significant cancer burdens 2 5.
What are the challenges and research gaps in preventing infection-related cancers?
While preventive strategies are effective, several challenges limit their impact, including under-recognition of the full disease burden, variable vaccine uptake, and emerging pathogens 5 7 9 12.
- Conservative estimates of infection prevalence and risk ratios likely understate the true impact of infectious agents on cancer 5.
- The effectiveness of HPV and other vaccines in preventing non-cervical cancers (e.g., head and neck cancers) requires more long-term data 7 9.
- Cofactors such as genetics, environment, and coinfections modify cancer risk but are incompletely understood, particularly for EBV-associated cancers 12.
- There is a need for improved surveillance, harmonization of epidemiological studies, and targeted interventions in high-risk populations 4 12.
Future Research Questions
Ongoing research is essential to refine our understanding of infection-related cancer epidemiology, improve preventive measures, and address gaps identified in current studies. Key questions include the long-term impact of vaccination, regional differences in infection-attributable cancers, and the role of emerging or less well-characterized pathogens.
| Research Question | Relevance |
|---|---|
| What is the long-term effectiveness of HPV and hepatitis vaccines in reducing cancer incidence? | Understanding long-term vaccine effectiveness is critical for optimizing immunization strategies and predicting future cancer trends, especially as current data are strongest for cervical cancer but less robust for other related cancers 6 7 10. |
| How do socioeconomic and regional factors influence the burden of infection-attributable cancers? | Regional disparities in infection prevalence and healthcare access lead to uneven cancer burdens; understanding these factors is key for effective targeting of public health interventions 1 2 3 4. |
| What are the most effective strategies for increasing vaccine coverage and reducing infection-related cancers in low-income countries? | Low-income regions bear a disproportionate share of infection-related cancers; research into scalable prevention and vaccination strategies is crucial for global cancer control 3 4 7. |
| Which emerging or under-recognized infectious agents may contribute to cancer risk? | Many estimates are conservative due to limited data on less common or novel pathogens; identifying additional agents could increase the preventable fraction of cancers 5 12. |
| How do host genetics and cofactors modify the risk of infection-related cancers? | Individual susceptibility is modified by genetic, environmental, and behavioral factors, which remain insufficiently characterized, especially for EBV- and HPV-related cancers 12. |